CHRNA2 and early-onset autosomal dominant Alzheimer disease: Additionally, the observed decrease in Aβ40 and Aβ42 levels in the brains of AOM/DSS-treated AppNL-G-F female mice compared to vehicle treated AppNL-G-F female mice, along with the upregulation of ADRB3 and CHRNA2, provides a complex picture of how systemic inflammation and local neurotransmitter signaling may interact with Alzheimer’s disease-related pathology.